Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiation for Newly Diagnosed Glioblastoma
NCT00884741Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2009
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of bevacizumab in glioblastoma (GBM), Gliosarcoma (GS), sponsored by National Cancer Institute. Started Apr 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00884741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884741.